Sunday, November 1, 2026

Bionano Genomics Stock Bearish By 16% So Far Today

Bionano Genomics Stock Bearish By 16% So Far Today

Bionano Genomics Inc. (NASDAQ: BNGO), a leading genome analysis software provider based out of San Diego, is currently experiencing a downturn in the stock market. Its shares have recently dropped by a substantial 16.74%, closing at $.89 on Tuesday. The decline appears to reflect an overall bearish trading sentiment, which has been observed over the previous two sessions of trading losses.

Previous Market Performance

Despite the current drop, Bionano's prior closing was robust at.67, which was standing 7.36% above its 52-week high of.35. Nonetheless, there has been evidence of market volatility recently. Both NASDAQ and Bionano saw declines, with NASDAQ falling 1.12% to close at 837.15 globally and Bionano dropping to its 52-week low of.35, indicating a general bearish sentiment for Bionano stocks.

Year-on-Year Quarterly Revenue Growth

An encouraging sign for Bionano is its year-on-year quarterly revenue growth reported recently. Bionano showed an impressive 30.2% spike, amounting to 29.52 million dollars over twelve months. However, despite this strong revenue growth, Bionano's stock value experienced a fall on Tuesday, though its value still exceeds both the 50-day moving average (sh.66) and the 200-day moving average (.35).

Trailing Twelve Months Statistics

Bionano's trailing twelve months EPS is at 0.45, a fact that demands consideration, particularly when looked at in the context of its ROE (Return on Equity). An ROE of negative 51.51% over the trailing twelve months suggests difficulty the company has faced generating profits against its shareholder equity. This, combined with an EBITDA of -6.46, provides a complex financial image for potential investors.

Investor Insight

The case of Bionano Genomics is useful in understanding that multiple factors can influence stock prices, including company fundamentals, market trends, and global sentiment. Bionano's recent decline underscores the inherent volatility of equity markets, proving that even significant internal growth can be outpaced by broader financial dynamics. This serves as a valuable reminder for investors to take a comprehensive view when making decisions, emphasizing the importance of financial literacy.

More news about Bionano Genomics (BNGO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,532 source documents archived
Query this data → isubstrate.com